-+ 0.00%
-+ 0.00%
-+ 0.00%

Lilly to buy Atai Beckley for USD 6.75 a share plus CVR up to USD 2.5

PUBT·07/16/2026 11:28:32
Listen to the news
Lilly to buy Atai Beckley for USD 6.75 a share plus CVR up to USD 2.5
  • Lilly agreed to buy Atai Beckley for USD 6.75 a share in cash, valuing the equity at about USD 2.8 billion.
  • Deal includes a CVR worth up to USD 2.5 a share tied to development and U.S. approval milestones for BPL-003, VLS-01.
  • Transaction is expected to close in the third quarter, subject to Atai Beckley stockholder vote and other customary conditions.
  • BPL-003 is an intranasal 5-MeO-DMT program for treatment-resistant depression; VLS-01 is a buccal DMT formulation in Phase 2b.
  • Offer represents about a 40% premium to the 30-day volume-weighted average share price through July 15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atai Beckley Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-028604), on July 16, 2026, and is solely responsible for the information contained therein.